Therefore, we hypothesized that combining anti-ANGPTL3 and IL-22 could simultaneously reduce proteinuria, mitigate the inflammatory response, and regulate metabolism homeostasis to achieve better DN treatment outcomes. This evidence concerns the gene IL22 and liver dysplastic nodule.